Peter E. Boyd

CIK: 0001739816

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (33.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)4 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AQST

Aquestive Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

AQST
Aquestive Therapeutics, Inc.
Sep 9, 2026
In-the-Money(X)
Direct
2.3K shares at avg. $0.96$2K
AQST
Aquestive Therapeutics, Inc.
May 5, 2026
Tax Payment(F)
Direct
56.8K shares at avg. $4.18$237K
AQST
Aquestive Therapeutics, Inc.
Mar 10, 2026
Sale(S)
Direct
29.8K shares at avg. $4.17$124K
AQST
Aquestive Therapeutics, Inc.
Mar 9, 2026
Award(A)
Direct
80K shares-
AQST
Aquestive Therapeutics, Inc.
Dec 4, 2025
Award(A)
Direct
20K shares-
AQST
Aquestive Therapeutics, Inc.
Oct 15, 2025
Sale(S)
Direct
10K shares at avg. $7.00$70K
AQST
Aquestive Therapeutics, Inc.
Sep 26, 2025
Sale(S)
Direct
10K shares at avg. $6.30$63K
AQST
Aquestive Therapeutics, Inc.
Sep 5, 2025
Sale(S)
Direct
15K shares at avg. $5.30$80K
AQST
Aquestive Therapeutics, Inc.
Mar 9, 2025
Tax Payment(F)
Direct
7.7K shares at avg. $2.65$20K
AQST
Aquestive Therapeutics, Inc.
Mar 7, 2025
Award(A)
Performance Stock Units
Direct
60K shares-
AQST
Aquestive Therapeutics, Inc.
Mar 7, 2025
Award(A)
Direct
80K shares-
AQST
Aquestive Therapeutics, Inc.
Mar 7, 2025
Tax Payment(F)
Direct
6.6K shares at avg. $2.65$18K

		Type	Shares	Price		Ownership
Sep 9, 2026	AQST Aquestive Therapeutics, Inc.	In-the-Money(X)	2,293	$0.96	$2,201	Direct
May 5, 2026	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	56,778	$4.18	$237,332	Direct
Mar 10, 2026	AQST Aquestive Therapeutics, Inc.	Sale(S)	29,814	$4.17	$124,414	Direct
Mar 9, 2026	AQST Aquestive Therapeutics, Inc.	Award(A)	80,000	-	$0	Direct
Dec 4, 2025	AQST Aquestive Therapeutics, Inc.	Award(A)	20,000	-	-	Direct
Oct 15, 2025	AQST Aquestive Therapeutics, Inc.	Sale(S)	10,000	$7.00	$70,000	Direct
Sep 26, 2025	AQST Aquestive Therapeutics, Inc.	Sale(S)	10,000	$6.30	$63,000	Direct
Sep 5, 2025	AQST Aquestive Therapeutics, Inc.	Sale(S)	15,000	$5.30	$79,500	Direct
Mar 9, 2025	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	7,681	$2.65	$20,355	Direct
Mar 7, 2025	AQST Aquestive Therapeutics, Inc.	Award(A) Performance Stock Units	60,000	-	-	Direct
Mar 7, 2025	AQST Aquestive Therapeutics, Inc.	Award(A)	80,000	-	-	Direct
Mar 7, 2025	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	6,624	$2.65	$17,554	Direct

1-12 of 12 transactions

About Boyd Peter E.

Boyd Peter E. (SEC CIK 0001739816) files insider reports with the SEC as Chief People Officer of Aquestive Therapeutics, Inc. (AQST).

Signal8 holds 9 ownership filings by Boyd Peter E., all Form 4s, filed between Mar 11, 2025 and Sep 10, 2026. Those filings report 12 transactions, from Mar 7, 2025 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Boyd Peter E.'s filings is in WARREN, NJ.

Recent filings by Boyd Peter E.

Sep 9, 2026: Option exercise of AQST shares (Form 4, code X).
May 5, 2026: Tax withholding of AQST shares (Form 4, code F).
Mar 10, 2026: Open-market sale of AQST shares (Form 4, code S).
Mar 9, 2026: Grant or award of AQST shares (Form 4, code A).
Dec 4, 2025: Grant or award of AQST shares (Form 4, code A).

Other insiders filing for Aquestive Therapeutics, Inc. (AQST)

Cochran John, Director
Barber Daniel, President and CEO
Daly Richard J, Director
Korczynski Sherry, Chief Commercial Officer
Jung Cassie, Chief Operating Officer
Krop Julie, Director

How to read Form 4 transaction codes